CLINICAL_TRIALS
withdrawal
· 2014-04-28
Clinical Trial Update: Rifaximin Treatment of Papulopustular Rosacea [Phase 2]
Summary
Phase 2 trial evaluating rifaximin for papulopustular rosacea has been withdrawn.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: University of California, San Francisco | Conditions: Rosacea | Phase 2 | Status: WITHDRAWN